Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 31;56(4):322-331.
doi: 10.5045/br.2021.2021101.

Real-life ruxolitinib experience in intermediate-risk myelofibrosis

Fatma Arikan  1 , Tayfur Toptas  1 , Isik Kaygusuz Atagunduz  1 , Tarik Ercan  1 , Ozen Oruc  1 , Fergun Yilmaz  1 , Tulin Tuglular  1
Affiliations

Real-life ruxolitinib experience in intermediate-risk myelofibrosis

Fatma Arikan et al. Blood Res. .

Abstract

Background: In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated.

Methods: The median age of the patients in this cohort was approximately 58 years. Of these, there were 33 patients (57.9%) in INT-1, 23 patients (40.4%) in INT-2, and 1 patient (1.8%) at high risk. Overall, spleen size reduction of at least 35% (spleen response) was achieved in 56.6% and 63.3% of all cohort and INT-1 risk at any time, respectively.

Results: Symptom response and clinical improvement were observed in 21.7% and 60.7% of patients, respectively. Anemia and thrombocytopenia were prevalent, but manageable. About 73.7% of patients continued treatment during a median follow-up of 22 months. Two-year OS probability was approximately 84.5% (95% CI, 63.1‒94.0%) and 62.3% (95% CI, 37.5‒79.6%) for the intermediate-1 and -2 risk groups, respectively.

Conclusion: Real-life experience in a community-based hospital confirms the efficacy and safety profile of ruxolitinib in intermediate-risk myelofibrosis. Treatment discontinuation rates were lower than those in clinical trials.

Keywords: Primary myelofibrosis; Ruxolitinib; Spleen response.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Spleen response at 6 months of treatment in the cohort (A). Spleen response at any time during the follow up in the cohort (B).
Fig. 2
Fig. 2
Overall survival in the cohort (A). Overall survival in intermediate-1 and -2 risk groups (B). Impact of baseline anemia on survival (C).
See this image and copyright information in PMC

References

    1. Cervantes F. How I treat myelofibrosis. Blood. 2014;124:2635–42. doi: 10.1182/blood-2014-07-575373. - DOI - PubMed
    1. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood. 2010;115:1703–8. doi: 10.1182/blood-2009-09-245837. - DOI - PubMed
    1. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–7. doi: 10.1200/JCO.2010.32.2446. - DOI - PubMed
    1. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for trans-plantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310–8. doi: 10.1200/JCO.2017.76.4886. - DOI - PubMed
    1. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis. J Clin Oncol. 2018;36:1769–70. doi: 10.1200/JCO.2018.78.9867. - DOI - PubMed